PYC Therapeutics Says Drug Candidate Shows Visual Acuity, Retinal Sensitivity Improvements in Eye Disease Trial

MT Newswires Live

Jun 23, 2025

PYC Therapeutics (ASX:PYC) said that its drug candidate, VP 001, designed to treat Retinitis Pigmentosa type 11, a blinding eye disease of childhood, has shown improvements in both visual acuity and retinal sensitivity in early-stage clinical trials, according to a Monday filing with the Australian bourse.

The improvements were observed using low luminance visual acuity (LLVA) and microperimetry assessments in patients dosed with VP 001, the filing said.

The company plans to advance the drug into a registrational trial, and recently held a Type B meeting with the US Food and Drug Administration, which confirmed LLVA or microperimetry could serve as standalone primary endpoints, the filing added.

A Type D meeting is expected in the second half of the year, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545457078"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545457078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545457078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545457078","market":"hk","top_or_hot":-1,"title":"PYC Therapeutics Says Drug Candidate Shows Visual Acuity, Retinal Sensitivity Improvements in Eye Disease Trial","media":"MT Newswires Live","content":"<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said that its drug candidate, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> 001, designed to treat Retinitis Pigmentosa type 11, a blinding eye disease of childhood, has shown improvements in both visual acuity and retinal sensitivity in early-stage clinical trials, according to a Monday filing with the Australian bourse.</p><p>The improvements were observed using low luminance visual acuity (LLVA) and microperimetry assessments in patients dosed with VP 001, the filing said.</p><p>The company plans to advance the drug into a registrational trial, and recently held a Type B meeting with the US Food and Drug Administration, which confirmed LLVA or microperimetry could serve as standalone primary endpoints, the filing added.</p><p>A Type D meeting is expected in the second half of the year, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PYC Therapeutics Says Drug Candidate Shows Visual Acuity, Retinal Sensitivity Improvements in Eye Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPYC Therapeutics Says Drug Candidate Shows Visual Acuity, Retinal Sensitivity Improvements in Eye Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-23 09:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PYC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:PYC) said that its drug candidate, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> 001, designed to treat Retinitis Pigmentosa type 11, a blinding eye disease of childhood, has shown improvements in both visual acuity and retinal sensitivity in early-stage clinical trials, according to a Monday filing with the Australian bourse.</p><p>The improvements were observed using low luminance visual acuity (LLVA) and microperimetry assessments in patients dosed with VP 001, the filing said.</p><p>The company plans to advance the drug into a registrational trial, and recently held a Type B meeting with the US Food and Drug Administration, which confirmed LLVA or microperimetry could serve as standalone primary endpoints, the filing added.</p><p>A Type D meeting is expected in the second half of the year, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545457078","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545457078","pubTimestamp":1750643453,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PYC Therapeutics  said that its drug candidate, VP 001, designed to treat Retinitis Pigmentosa type 11, a blinding eye disease of childhood, has shown improvements in both visual acuity and retinal sensitivity in early-stage clinical trials, according to a Monday filing with the Australian bourse.The improvements were observed using low luminance visual acuity  and microperimetry assessments in patients dosed with VP 001, the filing said.The company plans to advance the drug into a registrational trial, and recently held a Type B meeting with the US Food and Drug Administration, which confirmed LLVA or microperimetry could serve as standalone primary endpoints, the filing added.A Type D meeting is expected in the second half of the year, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4096":"电气部件与设备","AYI":"Acuity Brands Inc","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics","LU0054578231.USD":"BGF SYSTEMATIC SUSTAINABLE GLOBAL SMALLCAP \"A2\" (USD) ACC","PYC.AU":"PYC THERAPEUTICS LTD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4139":"生物科技"},"translate_title":"PYC Therapeutics表示候选药物在眼病试验中显示出视力和视网膜敏感性的改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"AYI":1,"PYC.AU":0.9},"content_text":"PYC Therapeutics (ASX:PYC) said that its drug candidate, VP 001, designed to treat Retinitis Pigmentosa type 11, a blinding eye disease of childhood, has shown improvements in both visual acuity and retinal sensitivity in early-stage clinical trials, according to a Monday filing with the Australian bourse.The improvements were observed using low luminance visual acuity (LLVA) and microperimetry assessments in patients dosed with VP 001, the filing said.The company plans to advance the drug into a registrational trial, and recently held a Type B meeting with the US Food and Drug Administration, which confirmed LLVA or microperimetry could serve as standalone primary endpoints, the filing added.A Type D meeting is expected in the second half of the year, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}